StartGIFOF • OTCMKTS
add
Grifols SA Preference Shares Class B
Seneste lukkekurs
7,42 $
Årsinterval
5,58 $ - 9,40 $
Markedsværdi
5,97 mia. USD
Gns. volumen
10,00
P/E-værdi
-
Udbytteprocent
-
Markedsnyheder
Økonomi
Resultatopgørelse
Indtægt
Nettoindtægt
(EUR) | sep. 2024info | År til år-ændring |
---|---|---|
Indtægt | 1,79 mia. | 12,24 % |
Driftsudgifter | 376,78 mio. | -3,08 % |
Nettoindtægt | 51,69 mio. | -13,19 % |
Overskudsgrad | 2,88 | -22,79 % |
Earnings per share | — | — |
EBITDA | 468,09 mio. | 33,73 % |
Effektiv afgiftssats | 31,35 % | — |
Årsbalance
Samlede aktiver
Samlede passiver
(EUR) | sep. 2024info | År til år-ændring |
---|---|---|
Kontanter og korttidsinvesteringer | 806,74 mio. | 66,60 % |
Samlede aktiver | 20,28 mia. | -8,07 % |
Samlede passiver | 12,29 mia. | -8,95 % |
Samlet egenkapital | 8,00 mia. | — |
Shares outstanding | 679,63 mio. | — |
Kurs/indre værdi | 0,94 | — |
Afkast af aktiver | 4,22 % | — |
Afkast af kapital | 4,78 % | — |
Pengestrøm
Nettoændring i likviditet
(EUR) | sep. 2024info | År til år-ændring |
---|---|---|
Nettoindtægt | 51,69 mio. | -13,19 % |
Pengestrøm fra drift | 299,61 mio. | 92,51 % |
Pengestrøm fra investering | -196,40 mio. | -59,83 % |
Pengestrøm fra finansiering | -1,56 mia. | -1.860,81 % |
Nettoændring i likviditet | -1,47 mia. | -3.652,69 % |
Fri pengestrøm | 243,60 mio. | 627,76 % |
Om
Grifols, S.A. is a global healthcare company and manufacturer of plasma-derived medicines founded in Barcelona, Spain, in 1909. With a workforce of over 23,000employees, Grifols serves more than 110 countries and regions and maintains a direct presence in over than 30.
Principally a producer of blood plasma–based products, a field in which it is the European leader and third largest worldwide, and other biopharmaceutical solutions, the company is also a leader in transfusion medicine, supplying devices, instruments and reagents for clinical testing laboratories, in addition to clinical diagnostic technologies. Its portfolio of solutions is designed to enhance safety from donation to transfusion. Grifols also provides high-quality biological supplies for life-science research, clinical trials and for manufacturing pharmaceutical and diagnostic products. Additionally, the company supply tools, information and services that enable hospitals, pharmacies and healthcare professionals to deliver expert medical care. Wikipedia
Administrerende direktør
Grundlagt
18. nov. 1940
Website
Ansatte
23.000